Abstract-The plasma and liver concentrations of both 1 -(tetrahydro-2-furanyl)-5 fluorouracil (FT) and 5-fluorouracil (5-FU), an active metabolite of FT, increased very markedly after administration of FT (500 mg/kg, p.o.) combined with L-cysteine (L-CYS, 500 mg/kg, i.p. or p.o.) when compared to FT alone in rats. On the other hand, the oral acute toxicity of FT was also enhanced with the combined administration of FT and L CYS. There was no difference in the in situ absorption rate of FT from the small intestine between rats treated with L-CYS (500 mg/kg, i.v.) and vehicle-treated controls. The inhibition of the disappearance of FT and the increase of the formation of 5-FU was observed in vitro after incubation of FT with liver microsomes from rats treated with L CYS (500 mg/kg, p.o.) when compared to vehicle-treated controls. The presence of L-CYS significantly inhibited the in vitro degradation of 5-FU by non-treated rat liver homogenate. In the drug metabolizing enzyme activity of rat liver microsomes, aniline p-hydroxylase activity was inhibited, but aminopyrine N-demethylase activity was conversely activated by the combined administration of FT and L-CYS, but not by FT alone; furthermore, no change of cytochrome P-450 content was observed. In sarcoma 180 bearing mice, the oral antitumor activity of FT in combination with L-CYS (500 mg/ kg, i.p. or p.o.) was about 1.1-2.0 times higher than that of FT alone. It was concluded from these findings that the drug metabolizing enzymes in liver involved in the conversion of FT into an active metabolite, 5-FU, are influenced by the combined administration of FT and L-CYS to give an increased organ level of 5-FU; and this resulted in the enhance ment of the antitumor activity of FT.
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1-(Tetrahydro-2-furanyl)
-5-fluorouracil (FT) is now widely used in cancer chemo therapy and is considered as a prodrug of 5-fluorouracil (5-FU) (1-3). Several papers revealed that the cytochrome P-450-mediated drug metabolizing enzymes of liver micro somes may participate in the conversion of FT to 5-FU (1, 4). Many attempts have been made to keep the higher concentration of 5-FU in tissues as well as in blood by using either inhibitors of 5-FU degradation such as uracil (5) (6) (7) or drug metabolizing enzyme inducers such as phenobarbital (4). Uracil is known to inhibit 5-FU degradation and to have no influence on drug metabolizing enzyme activities (7, 8) . When the drug metabolizing enzyme activities are low in cancer patients (9) , it seems difficult to obtain a high level of 5-FU in tissues by the combined administration with uracil. On the other hand, phenobarbital needs to be dosed for a few consecutive days before adminis tration of FT to induce the drug metabolizing enzyme activities; furthermore, the phar macological effects and development of tolerance of phenobarbital can not be dis regarded either. The induction of the drug metabolizing enzymes by phenobarbital is enhanced by the combined administration with glutathione (GSH) because GSH in creases the activities of drug metabolizing enzymes in the liver as a result of the in hibition of the lipid peroxidation which shares the electron transport system with the drug metabolizing enzymes (10, 11) . Recently, Yoshimura et al. (12) demon strated that orally administered GSH is poorly absorbed from the digestive tract; but L cysteine (L-CYS), a precursor of GSH, is well absorbed by the same route, resulting in the high liver level of GSH, which is syn thesized from L-CYS in vivo, as reported previously (13, 14) .
These findings prompted us to investigate the possibility for an increase in the concen trations of 5-FU in tissues by the treatment with FT combined with L-CYS, which might be followed by the enhancement in the antitumor activity of FT, and the effect of L-CYS on the metabolism of FT.
Materials and Methods
Animals: Male Wistar rats weighing 170 200 g and male ddy mice weighing 15-20 g were used in these experiments. The animals were maintained on a standard diet and water ad libitum in a room with controlled temperature (24°C) on a 12 hr light-dark cycle (7:00 a.m.-7:00 p.m.). Rats were fasted overnight before drug administration, but were given water ad libitum. (15) . All other reagents and solvents were analytical reagent grade. FT (150 mg/ml) and L-CYS (100 mg/ml) were administered in solutions of 1 M Na2CO3 and physiological saline, respectively. All solutions were pre pared immediately before use, and all doses in this study referred to the free drug.
Preparation of plasma and liver micro somes: Rats were lightly anesthetized with ethyl ether at definite times after drug adminis tration. Blood was drawn from the inferior vena cava into heparinized tubes after lapatomy. After centrifugation at 3,000 r.p.m. for 10 min, the resulting plasma was collected. The liver was perfused with 1.15% KCI and removed immediately after collecting blood which was omitted unless measuring the concentrations of FT and 5-FU in the plasma. The liver was minced and homogenized with 1.15% KCI or phosphate buffer with a Teflon glass homogenizer. The homogenate was centrifuged at 10,000 g for 20 min, and the resultant supernatant was centrifuged at 105,000 g for 60 min. The microsomal pellet was washed with a small amount of 1.15% KCI and then suspended in 1.15% KCI to a protein concentration of about 10 mg/ml. All procedures were performed at 4°C. Plasma and liver microsomal suspensions were stored under nitrogen at -70°C for subsequent analyses.
Determination of FT and 5-FU in plasma and liver: Rats were given FT alone at a dose of 500 mg/kg p.o. or combined with L-CYS at the same dose, i.p. or p.o., at 0, 3 and 6 hr after administration of FT. Plasma and livers were sampled at appropriate time intervals up to 12 hr after drug administration. Liver homogenate was prepared with 3 volumes of 0.25 M phosphate buffer (pH 6.0) in the manner described above.
The samples (1 ml) of plasma and 25% liver homogenate were deproteinized by adding 0.5 ml of ice-cold ethanol. After centrifugation at 3,000 r.p.m. for 10 min, 0.5 ml of the supernatant was removed and added to 0.5 ml of 0.25 M phosphate buffer (pH 6.0), then extracted with 8 ml of ethyl acetate. After centrifugation at 2,500 r.p.m. for 10 min, the organic layer was removed and evaporated to dryness under vacuum at room temperature. The residue was dissolved in 0.1 ml of orotic acid solution in methanol, corresponding to 30 and 150 jig/ml for plasma and liver, respectively, and 0.1 ml of ethereal diazomethane solution was added. The reaction mixture was evaporated to dryness under vacuum after standing for 30 min at room temperature, and the residue was dissolved in 100 /cl of acetone. A 1-2 id sample of this solution was injected into a Hewlett-Packard model 5710A GLC equipped with a nitrogen-phosphorus sensitive detector (NP-GLC). A 2 mx3 mm I.D. glass column packed with 1 % PEG-HT on 60-80 mesh Uniport HP (Gaschro Kogyo, Tokyo) was used for the chromatography. The temper atures of the injection port, column and detector were 300, 175 and 300°C, re spectively. Helium, the carrier gas, was maintained at a flow rate of 20 ml/min. The flow rates of air and hydrogen were optimized at 60 and 3 ml/min, respectively. The concen trations of FT in the plasma and liver were approx. 1,000 times higher than those of 5-FU, so the sensitivity of the instrument was lowered to 1 /20-1 /40 for FT after 5-FU and orotic acid were detected. Quantitation was accomplished by calibration curves obtained by plotting the ratio of the peak area of the methylated derivative of FT to that of orotic acid or the ratio of the peak height of the methylated derivative of 5-FU to that of orotic acid against the concentrations of these two compounds.
Acute toxicities: The 7 days acute toxicity tests in rats weighing 190-200 g were conducted to examine whether the oral toxicity of FT is altered by the combined administration of L-CYS (500 mg/kg, i.p. or p.o.). The LD50 values and its 95% con fidence limits were calculated according to Litchfield and Wilcoxon (16).
In situ absorption of FT: Rats were anes thetized with pentobarbital sodium (50 mg/ kg, i.p.) and the small intestine was can nulated for in situ recirculation according to the method of Schanker et al. (17) . The perfusion solution (pH 7.0) had the following composition (mM): NaCI, 73.6; Na2HP04. 12H20, 39.9; KH2PO4, 26.5 (18). Phenol red was contained in the solution (0.022 mM) in order to indicate the change of volume due to water absorption (17). The drug solution containing 2 mM FT was maintained at 37°C and was passed through the intestine at a flow rate of 3 ml/min. The rats were treated with L-CYS (500 mg/kg, i.v.) or the vehicle at 0, 0.5, 1 and 1.5 hr after the beginning of the perfusion. A 1 ml aliquot of the solution was removed at 0, 0.5, 1 and 2 hr after the perfusion was started. One half ml was used for the determination of FT by the spectro photometric assay method (19) , and the remaining 0.5 ml was used for the deter mination of phenol red (20) .
In vitro metabolism of FT: The liver micro somal suspension was prepared from rats 2 hr after treatment with L-CYS (500 mg/kg, p.o.) in the manner described above. Control rats were treated with the identical volume of the vehicle. The incubation mixture contain ing 0.5 mM FT, 0.5 mM NADP, 5 mM glucose-6-phosphate, 12 units of glucose-6 phosphate dehydrogenase, 0.1 mM EDTA, 5 mM MgSO4 and microsomal suspension (10 mg protein) in a total volume of 4 ml of 0.01 M phosphate buffer (pH 7.4) was incubated for 30 min at 37'C. The reaction was stopped by plunging it into an ice bath. A 1 ml aliquot of this solution was removed for subsequent determination of FT and 5-FU by N P-G LC in the manner described above.
In vitro degradation of 5-FU: A 25% (w/v) liver homogenate in 0.1 M phosphate buffer (pH 7.4) was prepared from non-treated rats in the manner described above. The incu bation mixture with a total volume of 1 ml of the homogenate containing 7.7 ,uM 5-FU alone or combined with 1 or 10 mM L-CYS was incubated at 37'C for 1.5 hr. The reaction was stopped by plunging it into an ice bath at 0.5, 1 and 1.5 hr after the beginning of the incubation, and the concentration of remaining 5-FU was determined by NP-GLC in the manner described above.
Drug metabolizing enzyme activities: Rats were treated with FT (500 mg/kg, p.o.) alone or combined with L-CYS (500 mg/kg, i.p. or p.o.). Control rats were treated with the identical volume of the vehicle. Two hr later, microsomes were prepared in the manner described above. The content of cytochrome P-450 was measured by the method of Omura and Sato (21) using the extinction coefficient of 91 mM-1 cm-1. Aniline p hydroxylase and aminopyrine N-demethylase activities were measured by determination of p-aminophenol formed according to the method of Schenkman (22) and formaldehyde formed by the method of Nash (23), re spectively. Microsomal protein was deter mined by the method of Lowry et al. (24) , using bovine serum albumin as the standard.
Chemotherapy experiments: Sarcoma 180 ascites tumor cells (5 x 106) were transplanted subcutaneously into the right axilla of mice. In situ absorption of FT: FT was absorbed rapidly from the rat small intestine in situ as shown in Fig. 3 . The percentages of the amounts of FT remaining in the perfusate of the vehicle-treated controls were 57.2, 30.2 and 16.1% at 0.5, 1.0 and 2.0 hr after the beginning of the perfusion, respectively. There was no significant difference in the amounts of FT absorbed from the small intestine between the rats that received L CYS (500 mg/kg, i.v.) at 0, 0.5, 1.0 and 1.5 hr after the beginning of the perfusion and the vehicle-treated controls (P<0.05).
In vitro metabolism of FT: The disappear Table 3 .
Effects of L-CYS on metabolism of FT with rat liver microsomes Liver microsomes were prepared from vehicle-treated control rats or rats 2 hr after treated with L-CYS (500 mg/kg, p.o.). Incubation was carried out with 0.5 mM FT, 0.5 mM NADP, 5 mM glucose-6 phosphate, 12 units of glucose-6-phosphate dehydrogenase, 0.1 mM EDTA, 5 mM MgSO4 and micro somes (10 mg protein) in a total volume of 4 ml of 0.01 M phosphate buffer (pH 7.4) for 30 min at 37 °C . Each value represents the mean+S.E. for 3 rats with the percentage change from the vehicle-treated control in parentheses.
Significantly different from the control, *P<0.05.
proportion to its concentration, and significant inhibitory effect was observed with 10 mM L-CYS in all incubation time examined. Effects of drug treatment on the liver microsomal drug metabolizing enzymes: The drug metabolizing enzyme activities in liver microsomes of the rats 2 hr after receiving FT (500 mg/kg, p.o.) alone or combined with L-CYS (500 mg/kg, i.p. or p.o.) were meas ured, and the results are shown in Table 4 Liver microsomes were prepared from vehicle-treated control rats or rats 2 hr after treatment with FT (500 mg/kg, p.o.) alone or combined with L-CYS (500 mg/kg, i.p. or p.o.). Concentrations of P-450, aniline (1 mM) p-hydroxylase and aminopyrine (1 mM) N-demethylase activities were measured as described under Materials and Methods. Each value represents the mean±S.E. for 4 rats with the percen tage change from the vehicle-treated control in parentheses.
Significantly different from the control, *P<0 .025, **P<0.005. 
Discussion
When FT (500 mg/kg, p.o.) was adminis tered with L-CYS (500 mg/kg, i.p. or p.o.) to rats, higher concentrations of FT and 5-FU in the plasma and liver were obtained as compared to the administration of FT alone (500 mg/kg, p.o.). The plasma and liver AUCO_12's of FT and 5-FU after adminis tration of FT combined with L-CYS were approx.
1.2-1.6 and 1.7-2.0 times, respectively, greater than those after FT alone. The t1/2 of FT in plasma was estimated to be 5.0 hr after administration of FT (500 mg/kg, p.o.) in close agreement with a report by Cohen (1) who showed that the t1/2 of FT given i.v. at a dose of 100 mg/kg was approx. 5.0 hr in the rat.
By the combined administration of L-CYS, however, the t1/2's of FT in plasma and liver were prolonged, while those of 5-FU were not changed. To elucidate the mechanism of increment in the organ levels of FT and 5-FU after administration of FT combined with L-CYS, the present studies were approached with special reference to the effects of L CYS on the metabolism of FT because little information from such a point of view is available.
Shimoyama et al. (25) have reported that FT was well absorbed from the small intestine of the rat, but scarcely from the stomach in an in situ recirculation system. Then, further investigation using the same system was aimed at examining whether L-CYS facilitates the intestinal absorption of FT. However, there was no difference in the absorption rate of FT from the small intestine between the rats treated with L-CYS (500 mg/kg, i.v.) and the vehicle-treated controls. Accordingly, the reason why the increased organ levels of FT and 5-FU were obtained by the combined administration of FT and L-CYS can not be explained by this absorption study.
It is well known that FT is biotransformed to an active metabolite, 5-FU, by microsomal drug metabolizing enzymes such as cyto chrome P-450 in liver (1-3). Then it can be predicted that the increase of the formation of 5-FU should be accompanied by the decrease of the concentration of FT through the enzymatic conversion by cytochrome P-450 in the liver. On the contrary, in the present study, not only the concentrations of 5-FU but also those of FT increased together in plasma and liver after administration of FT combined with L-CYS when compared to FT alone. Furthermore, when FT was used as a substrate for the liver microsomal drug metabolizing enzymes of the rats 2 hr after receiving L-CYS (500 mg/kg, p.o.), the disappearance of FT was significantly in hibited by 44.8%, while the formation of 5-FU was enhanced by 14.8% after incu bation for 30 min. Then the effect of L-CYS on the degradation of 5-FU formed in vivo after administration of FT was investigated in vitro with the liver homogenate of the non treated rats, taking it into account that the degradation of 5-FU occurs predominantly in the liver cytosolic fraction (8) . The de gradation of 5-FU was inhibited by L-CYS in proportion to its concentration in the incubation mixture. These findings suggest that L-CYS may affect preferentially the drug metabolizing enzyme systems responsi ble for the conversion of FT into 5-FU and/or their degradation, rather than the absorption step described above.
It has been demonstrated that the decrease in the activities of aniline p-hydroxylase and aminopyrine N-demethylase is caused by the induction of lipid peroxidation which shares the electron transport system with the drug metabolizing enzymes (11) , and the lipid peroxidation is inhibited by L-CYS and by GSH (10) which is formed from L-CYS in vivo (13, 14) . In the present studies, the activity of aniline p-hydroxylase was in hibited, but the activity of aminopyrine N demethylase was enhanced by the adminis tration of FT (500 mg/kg, p.o.) combined with L-CYS (500 mg/kg, i.p. or p.o.). However, the result obtained in this study that the concentrations of both FT and 5-FU increased after administration of FT combined with L-CYS can not be elucidated only by the inhibition of lipid peroxidation, which, of course, can not be ruled out and may play a partial role.
Recently, it has been proved that there are multiple forms of cytochrome P-450 which catalyze drug metabolism with their own substrate specificities (26, 27) , and the various forms of cytochrome P-450 also exhibit positional selectivity and stereoselec tivity in the oxidation of drugs (27) (28) (29) . Therefore, it can be supposed that the drug metabolizing enzyme activities in liver micro somes are influenced in the different manners by the administration of FT combined with L-CYS, except by FT alone, without any change in the concentration of cytochrome P-450.
Based on these findings, we would like to present the speculative scheme (Fig. 5 ) in which two metabolizing routes, I and II, of FT catalyzed by cytochrome P-450 are proposed in order to explain the results obtained in this study, and the metabolites of FT reported and/or presumed up to the present are also depicted (30) (31) (32) (33) . It has been proposed that 5-FU is not formed directly from FT enzymatically by cytochrome P-450 in liver, but via labile metabolic intermediates which could be easily transformed enzy matically or nonenzymatically to 5-FU (30, 33, 34) . Trans-3'-, cis-4' and traps-4'-OH FT are stable and not responsible either enzymatically or nonenzymatically for the formation of 5-FU as reported previously (33, 35) . 4', 5'-Dehydro-FT is formed not only in vivo but also in vitro by rat liver microsomes (32) . It is not apparent whether 4', 5' dehydro-FT could be formed by the de hydroxylation of 4' or 5'-OH-FT. Judging from the previous study that 4'-OH-FT could not be converted to 5-FU when incubated in plasma or the buffer (pH 9.0) at 37'C for 4 hr (35), 4', 5'-dehydro-FT might be formed via 5'-OH-FT from FT. In any case, 2'-, 5'-OH FT and 4', 5'-dehydro-FT are chemically labile, so could undergo nonenzymatic trans formation to 5-FU in vivo, and thus might serve as metabolic intermediates in the conversion of FT to 5-FU (30, 31, 33) . The metabolic route I, through which 3' and 4'-OH-FT could be formed, is perhaps in hibited by the administration of L-CYS and could result in the increase of the concen tration of FT. In contrast with this, the other route II, responsible for the formation of 2' and 5'-OH-FT, might be activated or at least unchanged by the administration of L-CYS. It is not clear whether this activation would be caused by the substantial activation of the cytochrome P-450's responsible for route II or attributable to the inhibition of those responsible for route I. The higher the concen tration of FT that would be obtained as a result of the inhibition of route I, the more 5-FU could be formed via route II.
It was strongly suggested from these results that the high organ levels of FT and 5-FU after administration of FT combined with L-CYS might cause the enhancement in the antitumor activity of FT. Then, we con ducted a preliminary experiment on the 
